


# Accepted Manuscript

Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials

Dean J. Kereiakes, Norman E. Lepor, Robert Gerber, L. Veronica Lee, Joe Ellassal, Desmond Thompson, C. Michael Gibson



PII: S0021-9150(18)31206-1

DOI: [10.1016/j.atherosclerosis.2018.07.010](https://doi.org/10.1016/j.atherosclerosis.2018.07.010)

Reference: ATH 15617

To appear in: *Atherosclerosis*

Received Date: 29 May 2018

Revised Date: 29 June 2018

Accepted Date: 6 July 2018

Please cite this article as: Kereiakes DJ, Lepor NE, Gerber R, Veronica Lee L, Ellassal J, Thompson D, Michael Gibson C, Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials, *Atherosclerosis* (2018), doi: 10.1016/j.atherosclerosis.2018.07.010.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

# Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase

## 3 trials

Dean J. Kereiakes <sup>a,\*</sup>, Norman E. Lepor <sup>b</sup>, Robert Gerber <sup>c</sup>, L. Veronica Lee <sup>d</sup>, Joe Ellassal <sup>e</sup>, Desmond Thompson <sup>e</sup> C. Michael Gibson <sup>f</sup>

<sup>a</sup> *The Christ Hospital, Heart and Vascular Center/The Lindner Research Center, Cincinnati, OH, USA*

<sup>b</sup> *Cedars-Sinai Medical Center/Westside Medical Associates of Los Angeles, Beverly Hills, CA, USA*

<sup>c</sup> *Department of Cardiology, East Sussex Healthcare NHS Trust, Hastings, UK*

<sup>d</sup> *Sanofi, Bridgewater, New Jersey;*

<sup>e</sup> *Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA*

<sup>f</sup> *Beth Israel Deaconess Medical Center, Boston, MA, USA*

\* Corresponding author:

Tel: +1 513 585 1777; Fax: +1 513 585 4858.

E-mail address: [Lindner@thechristhospital.com](mailto:Lindner@thechristhospital.com)

Dean J. Kereiakes, MD, FACC, FSCAI,

The Christ Hospital Heart and Vascular Center/The Lindner Research Center,

2123 Auburn Ave, Suite 424, Cincinnati, Ohio, USA

Download English Version:

<https://daneshyari.com/en/article/11030706>

Download Persian Version:

<https://daneshyari.com/article/11030706>

[Daneshyari.com](https://daneshyari.com)